SynthesisFrontiers in allergy2025
Thymic stromal lymphopoietin expression in different biological specimens in asthma: a systematic review and meta-analysis.
Synthesis in Frontiers in allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Precision medicine in asthma: endotype stratification, biomarker-guided biologics, and emerging therapeutic strategies.Molecular biology reports · 2026Review
- Tezepelumab: redefining TSLP blockade in severe asthma through mechanistic precision and translational pharmacology.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thymic stromal lymphopoietin (TSLP) is an epithelial-derived cytokine implicated in the pathogenesis of asthma. However, its expression across different biological specimens and its clinical correlates remain unclear. The objective of this study was to summarize available data on TSLP concentrations in blood and airway specimens in asthmatic patients. Methods: Studies reporting TSLP concentrations in blood and/or airway specimens [e.g., bronchial biopsy, bronchoalveolar lavage fluid (BALf), induced sputum, exhaled breath condensate (EBC), and nasal specimens] of asthmatic patients compared with healthy controls were eligible. PubMed, Web of Science, Embase, and Cochrane Library were searched from inception to October 2024. A total of 40 studies were included for qualitative synthesis, and 5 were eligible for meta-analysis. Differences in TSLP levels of asthmatic patients and controls were summarized by standardized mean differences (SMD) using a random effects model. Results: Based on meta-analysis, blood TSLP concentration was significantly higher in patients with asthma than in controls (SMD = 3.66, 95% CI 1.63-5.69, Conclusions: Most studies reported higher blood TSLP concentration in asthma patients compared with healthy controls, while results in airway specimens were diverse. Higher concentration of TSLP in asthmatic patients might be a useful disease-related marker. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024537964, PROSPERO CRD42024537964.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.